Abeona治疗学获得“Buy”共识, 目标为19.50美元, Abeona Therapeutics receives "Buy" consensus with $19.50 target, post-strong earnings report.

以稀有疾病为主的生物制药公司Abeona The Medicrotics(Abeona The Medicaltics)收到了五位分析家的“Buy”共识, 目标价格为19.50美元, Abeona Therapeutics, a biopharmaceutical company focused on rare diseases, received a "Buy" consensus with a $19.50 target price from five analysts, following its recent earnings report that beat expectations. 该公司的关键方案包括治疗上皮血解牛和Sanfilippo综合症。 The company's key programs include treatments for epidermolysis bullosa and Sanfilippo syndromes. 与GHO研究相比,Abeona被视为一种更好的投资,因为它拥有更高的机构所有权和分析师支持,尽管其股票价格更不稳定。 Compared to GH Research, Abeona is seen as a better investment due to its higher institutional ownership and analyst support, though it has a more volatile stock price.